Details checkedClinical trial listing onlyCheckedregistry

Drusen Mega plus Sertraline Antioxidant Tinnitus Study

Also known as: Sertraline, Sertraline Hydrochloride, Drusen Mega, Drusen Mega® + Sertraline, Placebo + Sertraline, NCT05646693

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 2

Status

Unknown

Target Gene

—

Route / Mode

Oral dietary supplement plus oral sertraline

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

Mexico

Population

adult, tinnitus, bilateral

Trial IDs

Mechanism

Phase 2 academic trial evaluating antioxidant dietary supplement Drusen Mega plus sertraline versus placebo plus sertraline in chronic subjective tinnitus, with oxidative-stress and inflammatory-cytokine endpoints.

Indications

Tinnitus

Notes

Corrected from a standalone sertraline row to the actual combination antioxidant-therapy study. Sertraline is used in both arms, while Drusen Mega is the experimental add-on; this should not be presented as a clean standalone sertraline tinnitus product program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT05646693

Open

Key Events

2022-12-01

Registry lists actual study start for Drusen Mega plus sertraline tinnitus study

Clinical Trials (1)

NCT05646693

Data Checks